Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lindsey M. Hoffman
Blinatumomab, a Bi-Specific Anti-Cd19/Cd3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
Frontiers in Oncology
Cancer Research
Oncology
Related publications
Blinatumomab in Acute Lymphoblastic Leukemia
Expert Review of Anticancer Therapy
Oncology
Pharmacology
Efficiency of Blinatumomab in a T(8;21) Acute Myeloid Leukemia Expressing CD19
Haematologica
Hematology
Pediatric Acute Lymphoblastic Leukemia
Hematology & Transfusion International Journal
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Advances in Therapy
Medicine
Pharmacology
Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression
American Journal of Hematology
Hematology
Treatment of CD19-Positive Mixed Phenotype Acute Leukemias With Blinatumomab
American Journal of Hematology
Hematology
Correlates of Resistance and Relapse During Blinatumomab Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
American Journal of Hematology
Hematology
Potential for Bispecific T-Cell Engagers: Role of Blinatumomab in Acute Lymphoblastic Leukemia
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia
Clinical Journal of Oncology Nursing
Oncology
